Patents for A61P 9 - Drugs for disorders of the cardiovascular system (159,484)
12/2002
12/17/2002US6495581 Drug for treating diabetes mellitus, hyperlipemia, impaired glucose tolerance, arterial sclerosis and improving insulin resistance, inflammatory disease
12/17/2002US6495578 Sulfonamide derivatives having oxadiazole rings
12/17/2002US6495574 Polyhydroxylated monocyclic N-heterocyclic derivatives as anti-coagulants
12/17/2002US6495568 Treatment of tissue ulceration, wound repair and skin diseases
12/17/2002US6495566 Potent antagonists at the strychnine insensitive glycine binding site associated with the n-methylaspartic acid receptor complex
12/17/2002US6495565 For therapy of acute infection, acute phase response, age related macular degeneration, alcoholism, anorexia, asthma, autoimmune disease, autoimmune hepatitis, bechet's disease, cachexia, calcium pyrophosphate dihydrtate deposition
12/17/2002US6495564 Such as 3-(6-((4-chloro-phenyl)-hydroxy-(3-methyl-3h-imidazol-4-yl)-methyl)-1-methyl-2-oxo-1,2-dihydro-quinolin-4-yl)-benzaldehyde o-methyl-oxime; inhibiting abnormal cell growth
12/17/2002US6495560 10,11-dihydro-3-(2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)-1 -ethoxy)-5h-dibenzo(a,d)cycloheptene-10-acetic acid; treatment of osteoporosis
12/17/2002US6495559 For therapy of obesity
12/17/2002US6495557 Condensed thienopyrimidines with phosphodiesterase-v inhibiting action
12/17/2002US6495554 Phosphodiesterase v inhibitors, treating cardiovascular disorders, and therapy of erectile dysfunction.
12/17/2002US6495552 Treatment or prevention of the diseases and conditions which respond to treatment by retinoids and or which in healthy mammals, including humans, are controlled by natural retinoic acid.
12/17/2002US6495545 1,4-benzodiazepinone derivatives and their use as integrin antagonists
12/17/2002US6495544 Homoiminopiperidinyl hexanoic acid inhibitors of inducible nitric oxide synthase
12/17/2002US6495543 Treating or preventing melatoninergic disorders
12/17/2002US6495542 Such as 2-methoxy-n-(2-methyl-1h-benzimidazol-4-yl)-4-(2,3,4,5-tetrahydro-5-oxo-1h-1-benzazepin-1-yl)carbonyl-benzam ide; hypertension, heart failure, renal insufficiency, edema, ascites, vasopressin parasecretion syndrome
12/17/2002US6495541 Tricyclic inhibitors of poly(ADP-ribose) polymerases
12/17/2002US6495533 Drugs containing phosphoric acid derivatives as the active ingredient
12/17/2002US6495526 Inhibitors of cell-cycle progression and uses related thereto
12/17/2002US6495525 N-((4-(((2-methylphenylamino)carbonyl)amino)phenyl)acetyl)-l -prolyl-3-methyl)-beta-alanine; very late antigen-4 cell adhesion inhibitor; inflammation and immune reactions
12/17/2002US6495523 Anticonvulsants; stroke, head trauma, spinal injury, non-fatal cardiac arrest, surgery
12/17/2002US6495522 Substituted alpha-hydroxy acid caspase inhibitors and the use thereof
12/17/2002US6495519 Interleukin-1 β converting enzyme like apoptosis protease-3 and 4
12/17/2002US6495517 Cyclooxygenase inhibitor
12/17/2002US6495516 Method for killing gram-negative bacteria with biologically active peptides from functional domains of bacterial/permeability-increasing protein
12/17/2002US6495346 Do not react with foreign partners; amino acids inserted into proteins which naturally form dimers, mutated proteins only form complexes with themselves (homodimers) or with the mutated partner (heterodimers), not with nonmutated starting
12/17/2002US6495338 Drug screening and diagnosis based on paracrine tubular renin-angiotensin system
12/17/2002US6495165 Eplerenone compositions having improved bioavailability
12/17/2002US6495148 High molecular weight polyuronic acids used as moisturizers and for prevention of skin disorders, ulcers, wrinkles, dryness or aging
12/17/2002CA2250420C Combinations of vasopressin and adrenergic agents for the treatment of cardiac arrest
12/17/2002CA2214439C A novel growth factor and a genetic sequence encoding same
12/14/2002CA2390686A1 Cofactor-based screening method for nuclear receptor modulators and related modulators
12/12/2002WO2002099115A2 Nucleic acid-associated proteins
12/12/2002WO2002099075A2 Prmts as modifiers of the p53 pathway and methods of use
12/12/2002WO2002099074A2 Slc7s as modifiers of the p53 pathway and methods of use
12/12/2002WO2002099060A2 Dgks as modifiers of the p53 pathway and methods of use
12/12/2002WO2002099040A2 Igs as modifiers of the p53 pathway and methods of use
12/12/2002WO2002099038A2 Adsls as modifiers of the p53 pathway and methods of use
12/12/2002WO2002098919A2 Method for apo ciii measurement in apob and non apob containing particles
12/12/2002WO2002098915A2 Compositions and methods for detecting or regulating cholesteryl ester transfer protein
12/12/2002WO2002098907A2 Cation conducting gabaa receptors and their use
12/12/2002WO2002098899A2 CHDs AS MODIFIERS OF THE p53 PATHWAY AND METHODS OF USE
12/12/2002WO2002098880A1 5-ethyl-imidazotriazinones
12/12/2002WO2002098878A1 Trifluoromethylpurines as phosphodiesterase 4 inhibitors
12/12/2002WO2002098877A1 Pyrazino 1',2':1,6 pyrido 3,4-b indole1,4-dione derivatives
12/12/2002WO2002098875A1 Carboline derivatives as pde-5 inhibitors
12/12/2002WO2002098873A1 2-heteroaryl-imidazotriazinones and their use in the treatment of inflammatory or immune diseases
12/12/2002WO2002098872A1 Isoindolines and process for preparation thereof
12/12/2002WO2002098871A1 Phenylcarboxamides and process for preparation thereof
12/12/2002WO2002098869A2 1,4-disubstituted benzo-fused cycloalkyl urea compounds
12/12/2002WO2002098868A1 Epothilone derivatives
12/12/2002WO2002098864A1 Pyrimidine, triazine and pyrazine derivatives as glutamate receptors
12/12/2002WO2002098863A1 Fused imidazole derivative
12/12/2002WO2002098858A1 Integrin antagonists
12/12/2002WO2002098852A2 Novel benzothienyl or indole derivatives, and use thereof as inhibitors of prenyl transferase proteins
12/12/2002WO2002098840A1 Carboxylic acid derivative and medicine comprising salt or ester of the same
12/12/2002WO2002098839A1 Biphenylcarboxamides and process for preparation thereof
12/12/2002WO2002098463A1 Antifungal compositions
12/12/2002WO2002098444A2 Use of hepcidin for preparing a medicament for treating disorders of iron homeostasis
12/12/2002WO2002098438A1 Compositions containing an active fraction isolated from scutellariae barbatae and methods of use
12/12/2002WO2002098431A1 Oxidant scavengers for treatment of diabetes or use in transplantation or induction of immune tolerance
12/12/2002WO2002098428A1 Tetracyclic compounds as pde5-inhibitors
12/12/2002WO2002098426A1 Substituted tetrahydroisoquinolines for use in the treatment of inflammatory diseases
12/12/2002WO2002098356A2 Ppp2cs as modifiers of the p53 pathway and methods of use
12/12/2002WO2002098351A2 Novel method and composition for inhibition of angiogenesis and tumor growth using compounds based on a sequence within mmp-2
12/12/2002WO2002098348A2 Glp-1 formulations with protracted time action
12/12/2002WO2002083879A3 Immunotherapy based on dendritic cells
12/12/2002WO2002080953A3 Method for reducing cellular damage resulting from hypoxia/ischaemia-related inflammation
12/12/2002WO2002076977A3 Rho-kinase inhibitors
12/12/2002WO2002076976A3 Rho-kinase inhibitors
12/12/2002WO2002072548A3 Heterocyclic compounds and their use as histamine h4 ligands.
12/12/2002WO2002069946A3 Use of triazole compounds for prophylaxis and in therapy for neurodegenerative illnesses, brain traumas and cerebral ischaemia
12/12/2002WO2002068015A9 Modular infusion device and method
12/12/2002WO2002066458A3 2-thio-substituted imidazole derivatives and the use thereof in the pharmaceutical industry
12/12/2002WO2002064591A3 Carboline derivatives
12/12/2002WO2002064552A8 1g(a)-AMINO-N-HYDROXY-ACETAMIDE DERIVATIVES
12/12/2002WO2002064080A3 Matrix metalloproteinase inhibitors
12/12/2002WO2002062792A9 Jnk inhibitor
12/12/2002WO2002061052A3 An improved in vitro method of culturing mammalian cells for autologous cell implantation/transplantation methods
12/12/2002WO2002053169A3 Use of dipeptylpeptidase iv and aminopeptidase-n inhibitors in the treatment of ischaemia-induced neuro-degeneration
12/12/2002WO2002046404A3 Schizophrenia-related voltage-gated ion channel gene and protein
12/12/2002WO2002032898A3 Novel anticholinergics, method for the production thereof and use thereof as medicaments
12/12/2002WO2002029044A3 Modulation of the transcription of pro-inflammatory gene products
12/12/2002WO2002018593A3 Modulation of fas and fasl expression
12/12/2002WO2002002775A3 Calpain protease 12
12/12/2002WO2001097850A3 Combinations and compositions which interfere with vegf/vegf and angiopoietin/tie receptor function and their use (ii)
12/12/2002WO2001089568A9 Nrg-2 nucleic acid molecules, polypeptides, and diagnostic and therapeutic methods
12/12/2002WO2001054731A3 Ligand conjugates and methods for preparing same
12/12/2002WO2001042272A9 Eplerenone crystalline form exhibiting enhanced dissolution rate
12/12/2002WO2001018207A9 Human 7tm proteins receptors and polynucleotides encoding the same
12/12/2002US20020188139 P-thienylbenzylamides as agonists of angiotensin-(1-7) receptors, and methods of their preparartion and use
12/12/2002US20020188128 Substituted imidazo[1,2-A] pyridine derivatives
12/12/2002US20020188124 Novel spiro compounds
12/12/2002US20020188122 Such as pyridine-4-carboxaldehyde-(4-Morpholinylprop-3-yl) imine for use in therapy as cytokine inhibitors
12/12/2002US20020188118 Compounds and methods for the inhibition of the expression of VCAM-1
12/12/2002US20020188018 3-indolyl-4-phenyl-1H-pyrrole-2,5-dione derivatives as inhibitors of glycogen synthase kinase-3beta
12/12/2002US20020188015 Method and composition for rejuvinating cells, tissues organs, hair and nails
12/12/2002US20020188009 Bisarylimidazolyl fatty acid amide hydrolase inhibitors
12/12/2002US20020188006 4-hydroxypiperidine derivatives having antiarrhythmic activity
12/12/2002US20020187999 Anti-inflammatory uses of manzamines